The Wyeth-Lederle heptavalent (types 4, 6B, 9V, 14, 18C, 19F, and 23F) pneumococcal vaccine contains pneumococcal polysaccharide conjugated to CRM197 diphtheria toxin. In an evaluation of safety and immunogenicity, this vaccine is being given to 300 infants at 2, 4, and 6 months of age in a double blind trial. Infants are randomized 2:1 with 2/3 receiving pneumococcal conjugate and 1/3 receiving meningococcal type C CRM197 conjugate(Wyeth-Lederle). Safety is being evaluated by telephone interviews at 2 & 7 days after each dose as well as through review of automated ER and hospital data. Immunogenicity is being evaluated for both vaccines with samples pre and 1 mo post 3rd dose. Only unblinded data is available to date for the three randomization groups (two pneumo, one mening). Review of local and systemic reactions following vaccine revealed reaction rates in the three groups to be similar to those observed in prior studies with wPDT-HbOC alone. There were no significant differences for fever, irritability, redness, swelling, or tenderness between the groups. Vaccine was well tolerated in the three groups. There were no cases of hives, general allergic reactions or neurologic reactions. At the time of presentation, unblinded safety and immunogenicity data will be available.